Compositions for immunotherapy and uses thereof

1. An immunogenic composition comprising a conjugate between an antigen and an oxidized mannan comprising mannose units and aldehyde groups, and a pharmaceutically acceptable carrier.

2. The composition of claim 1 wherein the antigen is a tumor antigen.

3. The composition of claim 2 wherein the antigen comprises part of a fusion polypeptide.

4. The conjugate of claim 2 wherein the tumor antigen is selected from the group consisting of melanoma specific antigen, carcino embryonic antigen (CEA) from colon cancer, p53, Her2/neu, ErB2, melan A, MAGE antigens, nm23, BRACA1, and BRACA2.

5. The composition of claim 1 , wherein the antigen is selected from the group consisting of pollens, hepatitis C virus (HIV) core, E1, E2 and NS2 proteins; Plasmodium faliciparum circumsporozoite protein; HIV-gp120/160 envelope glycoprotein; streptococcus surface protein Ag; influenza nucleoprotein; hemagglutinin-neuraminidase surface infection; TcpA pilin subunit; VP1 protein; LMCV nucleoprotein; Leishmania major surface glycoprotein (gp63); Bordetella pertussis surface protein; rabies virus G protein; Streptococcus M protein; respiratory syncytial virus (RSV) F or G proteins; Epstein Barr virus (EBV) gp340 or nucleoantigen 3A, hemagglutinin, Borrelia burgdorferi outer surface protein (Osp) A, Mycobacterium tuberculosis 38 kDa lipoprotein or Ag85 , Neisseria meningitides class 1 outer protein, Varicella zoster virus IE62 and gpI, Rubella virus capsid protein, Hepatitis B virus pre S1 ag, Herpes simplex virus type I glycoprotein G or gp D or CP27, Murray valley encephalitis virus E glycoprotein, Hepatitis A virus VP1, polio virus capsid protein VP1, VP2 and VP3, chlamydia trachomatis surface protein, Hepatitis B virus envelope Ag pre S2, Human rhinovirus (HRV) capsid, papillomavirus peptides from oncogene E6 and E7 , Listeria surface protein, Varicella virus envelope protein, Vaccinia virus envelope protein, Brucella surface protein, and a combination of one or more of said antigens.

6. The composition of claim 1 , wherein the antigen comprises whole cells or sub-cellular fractions thereof.

7. The composition of claim 6 wherein the whole cells or sub-cellular fractions thereof are, derived from tumor cells.

8. The conjugate of claim 7 wherein the tumor cells are selected from the group consisting of breast, lung, pancreas, colon and melanoma cells.

9. The composition of claim 4 or 5 wherein the antigen comprises part of a fusion polypeptide.